Personalized approaches for treatment-naïve mantle cell lymphoma Review


Authors: Qualls, D.; Kumar, A.
Review Title: Personalized approaches for treatment-naïve mantle cell lymphoma
Abstract: Introduction: Mantle cell lymphoma (MCL) can have diverse disease presentations, which vary in aggressiveness and prognosis, and can occur in patients with varying ability to tolerate therapy. Additionally, the options for treatment of MCL have expanded rapidly in the last decade, translating to improved outcome for patients. Areas covered: We review the initial evaluation of patients with MCL, identifying disease- and patient-specific prognostic factors, along with personalized therapies for patients with MCL. Specific scenarios include indolent and limited-stage MCL, advanced-stage disease in transplant-eligible and ineligible patients, and high-risk TP53 mutant disease. Ongoing trials and future directions in MCL treatment are also highlighted. Expert opinion: Given the wide array of disease and patient presentations with MCL, a personalized therapeutic approach is needed to optimize outcomes. The best therapeutic strategy should incorporate disease prognostic factors, patient status and comorbidities, goals of care, and response to treatment. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: adult; genetics; mantle cell lymphoma; immunotherapy; targeted therapy; lymphoma, mantle-cell; initial treatment; humans; prognosis; human; advances
Journal Title: Expert Review of Hematology
Volume: 16
Issue: 2
ISSN: 1747-4086
Publisher: Taylor & Francis Group  
Date Published: 2023-01-01
Start Page: 95
End Page: 107
Language: English
DOI: 10.1080/17474086.2023.2174516
PUBMED: 36748785
PROVIDER: scopus
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anita Kumar
    195 Kumar
  2. David Augustus Qualls
    21 Qualls